Abstract
An increasing curves of lymphoproliferative disorders incidence rates has been observed in many countries. This trend is more pronounced for Non-Hodgkin-s lymphomas (NHL) and it has been described by National Cancer Registry (NCR) in Czech Republic too, but there is a number of data problems which enables the appropriate analysis of NHL subtypes distribution as the outcome of patients.
Czech Lymphoma Study Group (CLSG) established the registry of newly diagnosed patients in 1999. Data of nearly 1400 patients were entered to the registry till 2002.
The main goal is the description of lymphoma subtypes distribution, overall survival analysis for different lymphoma subtypes and to use the registry for new lymphoma trials planning. The prerequisites are: the correct diagnosis confirmation by reference pathologists panel and the primary data quality.
Based on preliminary analyses the distribution of lymphoma subtypes is similar to other western countries. The overall survival (OS) could be preliminary analyzed in diffuse large B-cells lymphomas (n = 422) based on international prognostic score distribution with 2 years OS probability 93% for low risk, 78% for low intermediate risk, 44% for highintermediate and 36% for high risk patients.
The registry is very potent tool and could play very important role in prospective trials planning as the participation in international trials.